Abstract
S1P1 is an important target from GPCR family, whose crystal structure was released recently. Here, for the first time, we perform the 3D-QSAR analyses on a series of pyrazole oxadiazole derivatives, which are potent S1P1 agonists, by CoMFA and CoMSIA. We use two basic common cores, oxadiazole and pyrazole-oxadiazole, to align all compounds to establish the models of COMFA and COMSIA. The best CoMFA model by applying region focusing achieved a q2 of 0.736 and an r2 of 0.968. The actual predictive capabilities of the best CoMFA and CoMSIA models were then confirmed by the satisfactory predictions for the test set: rpred 2=0.762 for the best CoMFA model. Moreover, the contour maps derived from the best CoMFA and CoMSIA models are consistent with the biological activities of the studied compounds. Our results provide structural details about the interaction between S1P1 and small ligands. Our study is useful in guiding future design of more promising inhibitors of S1P1.
Letters in Drug Design & Discovery
Title:QSAR of Pyrazole Oxadiazole Derivatives as s1p1 Agonists Studied by CoMFA, CoMSIA and Docking
Volume: 10 Issue: 9
Author(s): Baokun Li, Tingjun Hou, Chongqian Zhang and Youyong Li
Affiliation:
Keywords: QSAR, drug design, S1P1, GPCR, CoMFA, CoMSIA.
Abstract: S1P1 is an important target from GPCR family, whose crystal structure was released recently. Here, for the first time, we perform the 3D-QSAR analyses on a series of pyrazole oxadiazole derivatives, which are potent S1P1 agonists, by CoMFA and CoMSIA. We use two basic common cores, oxadiazole and pyrazole-oxadiazole, to align all compounds to establish the models of COMFA and COMSIA. The best CoMFA model by applying region focusing achieved a q2 of 0.736 and an r2 of 0.968. The actual predictive capabilities of the best CoMFA and CoMSIA models were then confirmed by the satisfactory predictions for the test set: rpred 2=0.762 for the best CoMFA model. Moreover, the contour maps derived from the best CoMFA and CoMSIA models are consistent with the biological activities of the studied compounds. Our results provide structural details about the interaction between S1P1 and small ligands. Our study is useful in guiding future design of more promising inhibitors of S1P1.
Export Options
About this article
Cite this article as:
Li Baokun, Hou Tingjun, Zhang Chongqian and Li Youyong, QSAR of Pyrazole Oxadiazole Derivatives as s1p1 Agonists Studied by CoMFA, CoMSIA and Docking, Letters in Drug Design & Discovery 2013; 10 (9) . https://dx.doi.org/10.2174/15701808113109990001
DOI https://dx.doi.org/10.2174/15701808113109990001 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Calixarenes, Cyclodextrins and Fullerenes as New Platforms for Anti-HIV Drug Design: An Overview
Mini-Reviews in Medicinal Chemistry Pharmacological Applications of Lignins and Lignins Related Compounds: An Overview
Current Organic Chemistry Novel Targets for Antiinflammatory and Antiarthritic Agents
Current Pharmaceutical Design Combination of Phytosterols and Omega-3 Fatty Acids: A Potential Strategy to Promote Cardiovascular Health
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Controversies of Dopamine Agonists: Somnolence, Cardiac Valvulopathy and Repetitive Behaviors
Current Drug Therapy Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin
Current Cancer Drug Targets When BMP Signalling Goes Wrong: The Intracellular and Molecular Mechanisms of BMP Signalling in Cancer
Current Signal Transduction Therapy TNF-α Inhibitors with Anti-Oxidative Stress Activity from Natural Products
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Sensitive Sensors Based on Phosphorus Dendrimers
Current Organic Chemistry Inhibitors of ABL and the ABL-T315I Mutation
Current Topics in Medicinal Chemistry Nanoceria: A Novel Cytoprotective Drug Delivery Carrier
Current Nanomedicine Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Current Drug Discovery Technologies Histamine H4 Receptor: A Novel Therapeutic Target for Immune and Allergic Responses
Mini-Reviews in Medicinal Chemistry L-Type Voltage-Dependent Calcium Channels As Therapeutic Targets for Neurodegenerative Diseases
Current Medicinal Chemistry Measurement and Mapping of Retinal Leakage and Retinal Thickness - Surrogate Outcomes for the Initial Stages of Diabetic Retinopathy
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewing’s Sarcoma Tumor Cells
Current Pharmaceutical Biotechnology Nanosponges Encapsulated Phytochemicals for Targeting Cancer: A Review
Current Drug Targets